Risk factors of severe COVID-19 in people with multiple sclerosis : A systematic review and meta-analysis
To gather, synthesize, and meta-analyze data regarding the risk factors associated with a severe course of COVID-19 among patients with multiple sclerosis (pwMS). MEDLINE, Embase, Scopus, and WoS were searched in May 2021. Briefly, the eligibility criteria included: 1) studies assessing COVID-19 sev...
Gespeichert in:
| Veröffentlicht in: | Revue neurologique 2022-01, Vol.178 (1-2), p.121-128 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 128 |
|---|---|
| container_issue | 1-2 |
| container_start_page | 121 |
| container_title | Revue neurologique |
| container_volume | 178 |
| creator | Etemadifar, M. Nouri, H. Maracy, M.R. Akhavan Sigari, A. Salari, M. Blanco, Y. Sepúlveda, M. Zabalza, A. Mahdavi, S. Baratian, M. Sedaghat, N. |
| description | To gather, synthesize, and meta-analyze data regarding the risk factors associated with a severe course of COVID-19 among patients with multiple sclerosis (pwMS).
MEDLINE, Embase, Scopus, and WoS were searched in May 2021. Briefly, the eligibility criteria included: 1) studies assessing COVID-19 severity among adult pwMS; 2) definitive diagnoses or high clinical suspicion of COVID-19; 3) a categorization of COVID-19 severity into at least two categories; 4) quantitative effect size and precision measurements; and 5) English language; and 6) clear effect size/precision measures. internal validity of studies was assessed using the NIH Quality Assessment Tools. A list of possible risk factors was created based on the search results and was later used in extraction, synthesis, and meta-analysis of the data.
Thirteen studies were included in the syntheses. Outcome measures were either extracted from the papers, obtained from the primary researchers or calculated manually. The meta-analyses showed a significantly (P |
| doi_str_mv | 10.1016/j.neurol.2021.10.003 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8566345</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0035378721007438</els_id><sourcerecordid>2604019526</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3783-3fb0ace673aef41033d549f612dcd04ab73b54398b812a3956438bd83c948a023</originalsourceid><addsrcrecordid>eNp9UU1v1DAQtRCIfsA_QMhHLlnsjOM4HJCqBUqlSpUQcLUcZ0K9OPFiO1vtv8erLaVcuPhj5s2bmfcIecXZijMu325WMy4x-FXNal5CK8bgCTktZ1NBq9qnj94n5CylDSvAlsFzcgJCgZRMnRL3xaWfdDQ2h5hoGGnCHUak65vvVx8q3lE30y2GrUd65_ItnRaf3eGXrMcYkkv0Hb2gaZ8yTiY7SyPuHN5RMw90wmwqMxu_L7gX5NlofMKX9_c5-fbp49f15-r65vJqfXFd2TIpVDD2zFiULRgcBWcAQyO6UfJ6sAMTpm-hbwR0qle8NtA1UoDqBwW2E8qwGs7J-yPvduknHCzOORqvt9FNJu51ME7_m5ndrf4Rdlo1UoJoCsGbe4IYfi2Ysp5csui9mTEsSdeSCca7ppYFKo5QW6RIEceHNpzpg0t6o48u6YNLh2jxpJS9fjziQ9EfW_7ugEWoImfUyTqcLQ4uos16CO7_HX4DGrKmEg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2604019526</pqid></control><display><type>article</type><title>Risk factors of severe COVID-19 in people with multiple sclerosis : A systematic review and meta-analysis</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Etemadifar, M. ; Nouri, H. ; Maracy, M.R. ; Akhavan Sigari, A. ; Salari, M. ; Blanco, Y. ; Sepúlveda, M. ; Zabalza, A. ; Mahdavi, S. ; Baratian, M. ; Sedaghat, N.</creator><creatorcontrib>Etemadifar, M. ; Nouri, H. ; Maracy, M.R. ; Akhavan Sigari, A. ; Salari, M. ; Blanco, Y. ; Sepúlveda, M. ; Zabalza, A. ; Mahdavi, S. ; Baratian, M. ; Sedaghat, N.</creatorcontrib><description>To gather, synthesize, and meta-analyze data regarding the risk factors associated with a severe course of COVID-19 among patients with multiple sclerosis (pwMS).
MEDLINE, Embase, Scopus, and WoS were searched in May 2021. Briefly, the eligibility criteria included: 1) studies assessing COVID-19 severity among adult pwMS; 2) definitive diagnoses or high clinical suspicion of COVID-19; 3) a categorization of COVID-19 severity into at least two categories; 4) quantitative effect size and precision measurements; and 5) English language; and 6) clear effect size/precision measures. internal validity of studies was assessed using the NIH Quality Assessment Tools. A list of possible risk factors was created based on the search results and was later used in extraction, synthesis, and meta-analysis of the data.
Thirteen studies were included in the syntheses. Outcome measures were either extracted from the papers, obtained from the primary researchers or calculated manually. The meta-analyses showed a significantly (P<0.05) increased odds of a severe COVID-19 in pwMS with all of the assessed risk factors, except smoking and most DMTs.
This study facilitates evidence-based risk/benefit assessments in practice. Older men with progressive MS on anti-CD20 therapies are more at risk of an unfortunate COVID-19 outcome.</description><identifier>ISSN: 0035-3787</identifier><identifier>EISSN: 0035-3787</identifier><identifier>DOI: 10.1016/j.neurol.2021.10.003</identifier><identifier>PMID: 34836608</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Adult ; Aged ; COVID-19 ; Disease-modifying therapies ; Humans ; Male ; Meta-analysis ; Multiple sclerosis ; Multiple Sclerosis - complications ; Multiple Sclerosis - diagnosis ; Multiple Sclerosis - epidemiology ; Original ; Risk Factors ; SARS-CoV-2</subject><ispartof>Revue neurologique, 2022-01, Vol.178 (1-2), p.121-128</ispartof><rights>2021 Elsevier Masson SAS</rights><rights>Copyright © 2021 Elsevier Masson SAS. All rights reserved.</rights><rights>2021 Elsevier Masson SAS. All rights reserved. 2021 Elsevier Masson SAS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3783-3fb0ace673aef41033d549f612dcd04ab73b54398b812a3956438bd83c948a023</citedby><cites>FETCH-LOGICAL-c3783-3fb0ace673aef41033d549f612dcd04ab73b54398b812a3956438bd83c948a023</cites><orcidid>0000-0002-2796-6791</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0035378721007438$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34836608$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Etemadifar, M.</creatorcontrib><creatorcontrib>Nouri, H.</creatorcontrib><creatorcontrib>Maracy, M.R.</creatorcontrib><creatorcontrib>Akhavan Sigari, A.</creatorcontrib><creatorcontrib>Salari, M.</creatorcontrib><creatorcontrib>Blanco, Y.</creatorcontrib><creatorcontrib>Sepúlveda, M.</creatorcontrib><creatorcontrib>Zabalza, A.</creatorcontrib><creatorcontrib>Mahdavi, S.</creatorcontrib><creatorcontrib>Baratian, M.</creatorcontrib><creatorcontrib>Sedaghat, N.</creatorcontrib><title>Risk factors of severe COVID-19 in people with multiple sclerosis : A systematic review and meta-analysis</title><title>Revue neurologique</title><addtitle>Rev Neurol (Paris)</addtitle><description>To gather, synthesize, and meta-analyze data regarding the risk factors associated with a severe course of COVID-19 among patients with multiple sclerosis (pwMS).
MEDLINE, Embase, Scopus, and WoS were searched in May 2021. Briefly, the eligibility criteria included: 1) studies assessing COVID-19 severity among adult pwMS; 2) definitive diagnoses or high clinical suspicion of COVID-19; 3) a categorization of COVID-19 severity into at least two categories; 4) quantitative effect size and precision measurements; and 5) English language; and 6) clear effect size/precision measures. internal validity of studies was assessed using the NIH Quality Assessment Tools. A list of possible risk factors was created based on the search results and was later used in extraction, synthesis, and meta-analysis of the data.
Thirteen studies were included in the syntheses. Outcome measures were either extracted from the papers, obtained from the primary researchers or calculated manually. The meta-analyses showed a significantly (P<0.05) increased odds of a severe COVID-19 in pwMS with all of the assessed risk factors, except smoking and most DMTs.
This study facilitates evidence-based risk/benefit assessments in practice. Older men with progressive MS on anti-CD20 therapies are more at risk of an unfortunate COVID-19 outcome.</description><subject>Adult</subject><subject>Aged</subject><subject>COVID-19</subject><subject>Disease-modifying therapies</subject><subject>Humans</subject><subject>Male</subject><subject>Meta-analysis</subject><subject>Multiple sclerosis</subject><subject>Multiple Sclerosis - complications</subject><subject>Multiple Sclerosis - diagnosis</subject><subject>Multiple Sclerosis - epidemiology</subject><subject>Original</subject><subject>Risk Factors</subject><subject>SARS-CoV-2</subject><issn>0035-3787</issn><issn>0035-3787</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UU1v1DAQtRCIfsA_QMhHLlnsjOM4HJCqBUqlSpUQcLUcZ0K9OPFiO1vtv8erLaVcuPhj5s2bmfcIecXZijMu325WMy4x-FXNal5CK8bgCTktZ1NBq9qnj94n5CylDSvAlsFzcgJCgZRMnRL3xaWfdDQ2h5hoGGnCHUak65vvVx8q3lE30y2GrUd65_ItnRaf3eGXrMcYkkv0Hb2gaZ8yTiY7SyPuHN5RMw90wmwqMxu_L7gX5NlofMKX9_c5-fbp49f15-r65vJqfXFd2TIpVDD2zFiULRgcBWcAQyO6UfJ6sAMTpm-hbwR0qle8NtA1UoDqBwW2E8qwGs7J-yPvduknHCzOORqvt9FNJu51ME7_m5ndrf4Rdlo1UoJoCsGbe4IYfi2Ysp5csui9mTEsSdeSCca7ppYFKo5QW6RIEceHNpzpg0t6o48u6YNLh2jxpJS9fjziQ9EfW_7ugEWoImfUyTqcLQ4uos16CO7_HX4DGrKmEg</recordid><startdate>20220101</startdate><enddate>20220101</enddate><creator>Etemadifar, M.</creator><creator>Nouri, H.</creator><creator>Maracy, M.R.</creator><creator>Akhavan Sigari, A.</creator><creator>Salari, M.</creator><creator>Blanco, Y.</creator><creator>Sepúlveda, M.</creator><creator>Zabalza, A.</creator><creator>Mahdavi, S.</creator><creator>Baratian, M.</creator><creator>Sedaghat, N.</creator><general>Elsevier Masson SAS</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2796-6791</orcidid></search><sort><creationdate>20220101</creationdate><title>Risk factors of severe COVID-19 in people with multiple sclerosis : A systematic review and meta-analysis</title><author>Etemadifar, M. ; Nouri, H. ; Maracy, M.R. ; Akhavan Sigari, A. ; Salari, M. ; Blanco, Y. ; Sepúlveda, M. ; Zabalza, A. ; Mahdavi, S. ; Baratian, M. ; Sedaghat, N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3783-3fb0ace673aef41033d549f612dcd04ab73b54398b812a3956438bd83c948a023</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adult</topic><topic>Aged</topic><topic>COVID-19</topic><topic>Disease-modifying therapies</topic><topic>Humans</topic><topic>Male</topic><topic>Meta-analysis</topic><topic>Multiple sclerosis</topic><topic>Multiple Sclerosis - complications</topic><topic>Multiple Sclerosis - diagnosis</topic><topic>Multiple Sclerosis - epidemiology</topic><topic>Original</topic><topic>Risk Factors</topic><topic>SARS-CoV-2</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Etemadifar, M.</creatorcontrib><creatorcontrib>Nouri, H.</creatorcontrib><creatorcontrib>Maracy, M.R.</creatorcontrib><creatorcontrib>Akhavan Sigari, A.</creatorcontrib><creatorcontrib>Salari, M.</creatorcontrib><creatorcontrib>Blanco, Y.</creatorcontrib><creatorcontrib>Sepúlveda, M.</creatorcontrib><creatorcontrib>Zabalza, A.</creatorcontrib><creatorcontrib>Mahdavi, S.</creatorcontrib><creatorcontrib>Baratian, M.</creatorcontrib><creatorcontrib>Sedaghat, N.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Revue neurologique</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Etemadifar, M.</au><au>Nouri, H.</au><au>Maracy, M.R.</au><au>Akhavan Sigari, A.</au><au>Salari, M.</au><au>Blanco, Y.</au><au>Sepúlveda, M.</au><au>Zabalza, A.</au><au>Mahdavi, S.</au><au>Baratian, M.</au><au>Sedaghat, N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Risk factors of severe COVID-19 in people with multiple sclerosis : A systematic review and meta-analysis</atitle><jtitle>Revue neurologique</jtitle><addtitle>Rev Neurol (Paris)</addtitle><date>2022-01-01</date><risdate>2022</risdate><volume>178</volume><issue>1-2</issue><spage>121</spage><epage>128</epage><pages>121-128</pages><issn>0035-3787</issn><eissn>0035-3787</eissn><abstract>To gather, synthesize, and meta-analyze data regarding the risk factors associated with a severe course of COVID-19 among patients with multiple sclerosis (pwMS).
MEDLINE, Embase, Scopus, and WoS were searched in May 2021. Briefly, the eligibility criteria included: 1) studies assessing COVID-19 severity among adult pwMS; 2) definitive diagnoses or high clinical suspicion of COVID-19; 3) a categorization of COVID-19 severity into at least two categories; 4) quantitative effect size and precision measurements; and 5) English language; and 6) clear effect size/precision measures. internal validity of studies was assessed using the NIH Quality Assessment Tools. A list of possible risk factors was created based on the search results and was later used in extraction, synthesis, and meta-analysis of the data.
Thirteen studies were included in the syntheses. Outcome measures were either extracted from the papers, obtained from the primary researchers or calculated manually. The meta-analyses showed a significantly (P<0.05) increased odds of a severe COVID-19 in pwMS with all of the assessed risk factors, except smoking and most DMTs.
This study facilitates evidence-based risk/benefit assessments in practice. Older men with progressive MS on anti-CD20 therapies are more at risk of an unfortunate COVID-19 outcome.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>34836608</pmid><doi>10.1016/j.neurol.2021.10.003</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-2796-6791</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0035-3787 |
| ispartof | Revue neurologique, 2022-01, Vol.178 (1-2), p.121-128 |
| issn | 0035-3787 0035-3787 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8566345 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Aged COVID-19 Disease-modifying therapies Humans Male Meta-analysis Multiple sclerosis Multiple Sclerosis - complications Multiple Sclerosis - diagnosis Multiple Sclerosis - epidemiology Original Risk Factors SARS-CoV-2 |
| title | Risk factors of severe COVID-19 in people with multiple sclerosis : A systematic review and meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T00%3A10%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Risk%20factors%20of%20severe%20COVID-19%20in%20people%20with%20multiple%20sclerosis%20:%20A%20systematic%20review%20and%20meta-analysis&rft.jtitle=Revue%20neurologique&rft.au=Etemadifar,%20M.&rft.date=2022-01-01&rft.volume=178&rft.issue=1-2&rft.spage=121&rft.epage=128&rft.pages=121-128&rft.issn=0035-3787&rft.eissn=0035-3787&rft_id=info:doi/10.1016/j.neurol.2021.10.003&rft_dat=%3Cproquest_pubme%3E2604019526%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2604019526&rft_id=info:pmid/34836608&rft_els_id=S0035378721007438&rfr_iscdi=true |